Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Assets: 2014-2024

Historic Assets for Zevra Therapeutics (ZVRA) over the last 9 years, with Dec 2024 value amounting to $178.1 million.

  • Zevra Therapeutics' Assets rose 41.02% to $270.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $270.1 million, marking a year-over-year increase of 41.02%. This contributed to the annual value of $178.1 million for FY2024, which is 3.37% up from last year.
  • As of FY2024, Zevra Therapeutics' Assets stood at $178.1 million, which was up 3.37% from $172.3 million recorded in FY2023.
  • Zevra Therapeutics' Assets' 5-year high stood at $178.1 million during FY2024, with a 5-year trough of $11.2 million in FY2020.
  • Its 3-year average for Assets is $155.3 million, with a median of $172.3 million in 2023.
  • Its Assets has fluctuated over the past 5 years, first skyrocketed by 1,086.02% in 2021, then declined by 13.24% in 2022.
  • Over the past 5 years, Zevra Therapeutics' Assets (Yearly) stood at $11.2 million in 2020, then skyrocketed by 1,086.02% to $132.9 million in 2021, then fell by 13.24% to $115.3 million in 2022, then soared by 49.41% to $172.3 million in 2023, then climbed by 3.37% to $178.1 million in 2024.